219 related articles for article (PubMed ID: 32355214)
1. Transcriptional Upregulation of NLRC5 by Radiation Drives STING- and Interferon-Independent MHC-I Expression on Cancer Cells and T Cell Cytotoxicity.
Zebertavage LK; Alice A; Crittenden MR; Gough MJ
Sci Rep; 2020 Apr; 10(1):7376. PubMed ID: 32355214
[TBL] [Abstract][Full Text] [Related]
2. NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
Yoshihama S; Roszik J; Downs I; Meissner TB; Vijayan S; Chapuy B; Sidiq T; Shipp MA; Lizee GA; Kobayashi KS
Proc Natl Acad Sci U S A; 2016 May; 113(21):5999-6004. PubMed ID: 27162338
[TBL] [Abstract][Full Text] [Related]
3. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
[TBL] [Abstract][Full Text] [Related]
4. CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine.
Accolla RS; Ramia E; Tedeschi A; Forlani G
Front Immunol; 2019; 10():1806. PubMed ID: 31417570
[TBL] [Abstract][Full Text] [Related]
5. Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance.
Zheng W; Skowron KB; Namm JP; Burnette B; Fernandez C; Arina A; Liang H; Spiotto MT; Posner MC; Fu YX; Weichselbaum RR
Oncotarget; 2016 Jul; 7(28):43039-43051. PubMed ID: 27343548
[TBL] [Abstract][Full Text] [Related]
6. Hippo-signaling-controlled MHC class I antigen processing and presentation pathway potentiates antitumor immunity.
Peng L; Zhou L; Li H; Zhang X; Li S; Wang K; Yang M; Ma X; Zhang D; Xiang S; Duan Y; Wang T; Sun C; Wang C; Lu D; Qian M; Wang Z
Cell Rep; 2024 Apr; 43(4):114003. PubMed ID: 38527062
[TBL] [Abstract][Full Text] [Related]
7. NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.
van Montfoort N; Borst L; Korrer MJ; Sluijter M; Marijt KA; Santegoets SJ; van Ham VJ; Ehsan I; Charoentong P; André P; Wagtmann N; Welters MJP; Kim YJ; Piersma SJ; van der Burg SH; van Hall T
Cell; 2018 Dec; 175(7):1744-1755.e15. PubMed ID: 30503208
[TBL] [Abstract][Full Text] [Related]
8. Deficiency of the NOD-Like Receptor NLRC5 Results in Decreased CD8
Lupfer CR; Stokes KL; Kuriakose T; Kanneganti TD
J Virol; 2017 Sep; 91(17):. PubMed ID: 28615208
[TBL] [Abstract][Full Text] [Related]
9. Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation.
Chen J; Cao Y; Markelc B; Kaeppler J; Vermeer JA; Muschel RJ
J Clin Invest; 2019 Oct; 129(10):4224-4238. PubMed ID: 31483286
[TBL] [Abstract][Full Text] [Related]
10. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
Tanaka Y; Koido S; Ohana M; Liu C; Gong J
J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
[TBL] [Abstract][Full Text] [Related]
11. Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression.
Kriegsman BA; Vangala P; Chen BJ; Meraner P; Brass AL; Garber M; Rock KL
J Immunol; 2019 Oct; 203(7):1999-2010. PubMed ID: 31471524
[TBL] [Abstract][Full Text] [Related]
12. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
[TBL] [Abstract][Full Text] [Related]
13. Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation.
Xu H; Van der Jeught K; Zhou Z; Zhang L; Yu T; Sun Y; Li Y; Wan C; So KM; Liu D; Frieden M; Fang Y; Mosley AL; He X; Zhang X; Sandusky GE; Liu Y; Meroueh SO; Zhang C; Wijeratne AB; Huang C; Ji G; Lu X
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33830945
[TBL] [Abstract][Full Text] [Related]
14. LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer.
Zhan L; Zhang J; Zhang J; Liu X; Zhu S; Shi Y; He Y; Wang W; Fan Y; Tang Z; Chen G; Wei B; Cao Y
Cancer Lett; 2022 Mar; 529():37-52. PubMed ID: 34974132
[TBL] [Abstract][Full Text] [Related]
15. Photothermally Controlled MHC Class I Restricted CD8
Cao F; Yan M; Liu Y; Liu L; Ma G
Adv Healthc Mater; 2018 May; 7(10):e1701439. PubMed ID: 29508543
[TBL] [Abstract][Full Text] [Related]
16. A STING-activating nanovaccine for cancer immunotherapy.
Luo M; Wang H; Wang Z; Cai H; Lu Z; Li Y; Du M; Huang G; Wang C; Chen X; Porembka MR; Lea J; Frankel AE; Fu YX; Chen ZJ; Gao J
Nat Nanotechnol; 2017 Jul; 12(7):648-654. PubMed ID: 28436963
[TBL] [Abstract][Full Text] [Related]
17. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
[TBL] [Abstract][Full Text] [Related]
18. The N-terminal domain of NLRC5 confers transcriptional activity for MHC class I and II gene expression.
Neerincx A; Jakobshagen K; Utermöhlen O; Büning H; Steimle V; Kufer TA
J Immunol; 2014 Sep; 193(6):3090-100. PubMed ID: 25127861
[TBL] [Abstract][Full Text] [Related]
19. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
[TBL] [Abstract][Full Text] [Related]
20. NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens.
Yao Y; Wang Y; Chen F; Huang Y; Zhu S; Leng Q; Wang H; Shi Y; Qian Y
Cell Res; 2012 May; 22(5):836-47. PubMed ID: 22491475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]